Protective monocytes in cerebral ischemic tolerance
脑缺血耐受中的保护性单核细胞
基本信息
- 批准号:8422072
- 负责人:
- 金额:$ 36.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-15 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdoptive TransferAnimalsAutomobile DrivingBiological PreservationBloodBlood - brain barrier anatomyBlood flowBrainBrain DeathBrain InjuriesCell TherapyCellsCerebral IschemiaCerebrumClinical TrialsCytoprotectionDiseaseEngraftmentFlow CytometryGenesGlucoseGoalsImmuneImmune responseImmune systemImmunosuppressionInflammatoryIntrinsic factorIschemiaIschemic Brain InjuryIschemic StrokeKnockout MiceLigandsLipopolysaccharidesMolecularMusNeurological outcomeNeuronsOrganOxygenPathway interactionsPlayPopulationRecruitment ActivityResearchRoleStimulusStressStrokeTestingTherapeuticTimebasecell typecellular targetingclinically relevantdeprivationin vivoinsightmacrophagemeetingsmonocytemouse modelnervous system disorderneuroprotectionnovelnovel therapeutic interventionpreconditioningprogramsprotective effectsuccesstoll-like receptor 4trafficking
项目摘要
DESCRIPTION (provided by applicant): Stroke is a highly prevalent and devastating disease with limited therapeutic options. Most efforts to develop treatments for stroke have thus far met with limited success in large clinical trials. The brain has an enormous capacity for self-preservation, and elucidating how the brain protects itself may provide novel insights into stroke treatment. Ischemic tolerance (IT), a phenomenon in which application of sub-lethal stress [preconditioning (PC) stimulus; PC] induces a state of tolerance to a subsequent ischemic insult, represents an example of endogenous neuroprotection. IT can be induced in brain by systemic administration of the Toll-like receptor-4 ligand lipopolysaccharide (LPS). Different populations of immune cell could potentially play a role in PC induced by LPS. In particular, monocytes, which are the main target of LPS, can exert a powerful protective effect either directly or by modulating the immune system. However, it remains to be established whether monocytes or other immune cells play a role in the IT induced by LPS. The identification of the cell type(s) responsible for LPS induced IT would be important as it would offer the prospect of novel therapies for ischemic stroke based on these protective immune cells. This application will test the hypothesis that LPS PC induces brain engraftment of protective monocytic cells that ameliorate ischemic brain injury either directly or by modulating the immune response to cerebral ischemia. To this end, we will determine (a) the origin of neuroprotective monocytic subtypes, (b) the molecular factors driving their entry into the brain, and (c) the mechanisms by which they confer neuroprotection. Furthermore, we will determine whether these cells can be adoptively transferred to protect animals from experimental stroke with a clinically relevant therapeutic window. These goals will be achieved using a mouse model of transient focal cerebral ischemia with assessment of histological and neurological outcome. The effect of LPS PC on immune cell populations will be assessed by flow cytometry.
PUBLIC HEALTH RELEVANCE: Stroke caused by insufficient blood flow to the brain (ischemic stroke) is a leading cause of brain damage and death, but there is a paucity of therapies to protect the brain from its devastating effects. Our studies will explore new ways to dampen stroke damage based on the body's own ability to protect the brain. In particular, we will examine whether certain immune cells (monocytes) can make the brain more tolerant to the lack of blood that causes the stroke. The findings offer the prospect of using these monocytes as a novel treatment for acute ischemic stroke.
描述(由申请人提供):中风是一种高度流行和毁灭性的疾病,治疗选择有限。迄今为止,大多数开发中风治疗方法的努力在大型临床试验中取得了有限的成功。大脑具有巨大的自我保护能力,阐明大脑如何保护自己可能会为中风治疗提供新的见解。缺血耐受(IT)是一种应用亚致死应激[预处理(PC)刺激; PC]诱导对随后缺血性损伤耐受的现象,代表了内源性神经保护的一个例子。通过全身给予Toll样受体-4配体脂多糖(LPS)可以在脑中诱导IT。不同的免疫细胞群体可能在LPS诱导的PC中发挥作用。特别是,单核细胞是LPS的主要靶点,可以直接或通过调节免疫系统发挥强大的保护作用。然而,单核细胞或其他免疫细胞是否在LPS诱导的IT中发挥作用仍有待确定。鉴定负责LPS诱导的IT的细胞类型将是重要的,因为它将提供基于这些保护性免疫细胞的缺血性中风的新疗法的前景。本申请将测试LPS PC诱导保护性单核细胞的脑植入的假设,所述保护性单核细胞直接或通过调节对脑缺血的免疫应答来改善缺血性脑损伤。为此,我们将确定(a)神经保护性单核细胞亚型的起源,(B)驱动它们进入大脑的分子因素,以及(c)它们赋予神经保护作用的机制。此外,我们将确定这些细胞是否可以过继转移,以保护动物免受临床相关治疗窗口的实验性中风。这些目标将使用短暂局灶性脑缺血小鼠模型实现,并评估组织学和神经学结局。将通过流式细胞术评估LPS PC对免疫细胞群的影响。
公共卫生关系:脑血流不足引起的中风(缺血性中风)是脑损伤和死亡的主要原因,但缺乏保护大脑免受其破坏性影响的治疗方法。我们的研究将探索基于身体自身保护大脑的能力来减轻中风损害的新方法。特别是,我们将研究某些免疫细胞(单核细胞)是否可以使大脑更耐受导致中风的血液缺乏。这些发现为利用这些单核细胞作为急性缺血性卒中的新疗法提供了前景。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Josef Anrather其他文献
Josef Anrather的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Josef Anrather', 18)}}的其他基金
The Role of Dendritic Cells in Regulating the Gut-Brain Immune Axis in Ischemic Stroke
树突状细胞在调节缺血性中风肠脑免疫轴中的作用
- 批准号:
10680797 - 财政年份:2023
- 资助金额:
$ 36.97万 - 项目类别:
Protective monocytes in cerebral ischemic tolerance
脑缺血耐受中的保护性单核细胞
- 批准号:
8544515 - 财政年份:2012
- 资助金额:
$ 36.97万 - 项目类别:
Protective monocytes in cerebral ischemic tolerance
脑缺血耐受中的保护性单核细胞
- 批准号:
10439641 - 财政年份:2012
- 资助金额:
$ 36.97万 - 项目类别:
Protective monocytes in cerebral ischemic tolerance
脑缺血耐受中的保护性单核细胞
- 批准号:
9058617 - 财政年份:2012
- 资助金额:
$ 36.97万 - 项目类别:
Protective monocytes in cerebral ischemic tolerance
脑缺血耐受中的保护性单核细胞
- 批准号:
10220141 - 财政年份:2012
- 资助金额:
$ 36.97万 - 项目类别:
Protective monocytes in cerebral ischemic tolerance
脑缺血耐受中的保护性单核细胞
- 批准号:
8656165 - 财政年份:2012
- 资助金额:
$ 36.97万 - 项目类别:
Role of NF-kappaB phosphorylation in inflammatory signaling
NF-κB 磷酸化在炎症信号传导中的作用
- 批准号:
7215568 - 财政年份:2005
- 资助金额:
$ 36.97万 - 项目类别:
Role of NF-kappaB phosphorylation in inflammatory signaling
NF-κB 磷酸化在炎症信号传导中的作用
- 批准号:
7034633 - 财政年份:2005
- 资助金额:
$ 36.97万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 36.97万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 36.97万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 36.97万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 36.97万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 36.97万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 36.97万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 36.97万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 36.97万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 36.97万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 36.97万 - 项目类别: